drugset / Trial / NCT00813449

Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma

NCT00813449

Phase 2 Unknown 140 enrolled Simcere Pharmaceutical Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma, To compare the efficacy and safety of Endostar combined with Dacarbazine and monotherapy of Dacarbazine for advanced melanoma

Timeline

Start
2008-08
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule
Subject Endostar Protein / enzyme biologic

Indications